Clinical trial
Expanded Access Use of 18F-L-Fluoro-DOPA PET/CT Scan Localization of Focal Pancreatic Lesions in Subjects With Hyperinsulinemic Hypoglycemia
Name
12-009528
Description
This purpose of this study is to determine the ability of an 18F-fluoro-L-dihydroxyphenylalanine (18F-DOPA) PET (Positron Emission Tomography) scan to detect a focal lesion of hyperinsulinism and determine the location in patients with congenital hyperinsulinism, Beckwith Wiedemann Syndrome and suspected insulinoma. Safety data will be collected.
Trial arms
Treatment
18F-DOPA
18F-DOPA is a PET scan radiotracer.
Other names:
18F-fluoro-L-dihydroxyphenylalanine, 18F-L-Fluoro-DOPA
Size
-1
Eligibility criteria
Inclusion Criteria:
* Subjects of any age with hyperinsulinemic hypoglycemia, diagnosed by a fasting test and/or response to glucagon stimulation.
* Subjects who are eligible for pancreatic surgery regardless of prior pancreatic surgery
Exclusion Criteria:
* Pregnant or lactating females
* Any other major illness or condition that in the investigator's judgment will substantially increase the risk associated with the subject's participation in this study
* Subjects who are not a candidate for pancreatic surgery
Protocol
{'studyType': 'EXPANDED_ACCESS'}
Updated at
2024-04-04
1 organization
1 product
3 indications
Organization
Children's Hospital of PhiladelphiaProduct
18F-DOPAIndication
Congenital HyperinsulinismIndication
Beckwith-Wiedemann SyndromeIndication
Insulinoma